Table II.
Association between abnormal expression levels of miR-23a and miR-23b and the clinicopathological parameters of ovarian cancer.
| miR-23a | miR-23b | ||||||
|---|---|---|---|---|---|---|---|
| Clinicopathological parameters | n | High expression (n, %) | χ2 | P-value | Low expression (n, %) | χ2 | P-value |
| Age | 0.25 | >0.05 | 0.09 | >0.05 | |||
| ≥50 years old | 33 | 18 (54.55) | 16 (48.48) | ||||
| <50 years old | 17 | 8 (47.06) | 9 (52.94) | ||||
| Differentiation degree | 7.96 | <0.01 | 13.88 | <0.01 | |||
| Low differentiation | 21 | 6 (28.57) | 4 (19.05) | ||||
| Medium/high differentiation | 29 | 20 (68.97) | 21 (72.41) | ||||
| Metastasis of lymph nodes | 11.76 | <0.01 | 19.10 | <0.01 | |||
| Yes | 31 | 22 (70.97) | 23 (74.19) | ||||
| No | 19 | 4 (21.05) | 2 (10.53) | ||||
| Clinical staging | 6.61 | <0.05 | 5.56 | <0.05 | |||
| I–II | 18 | 5 (27.78) | 5 (27.78) | ||||
| III–IV | 32 | 21 (65.63) | 20 (62.50) | ||||
miR, microRNA.